Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II), a company active in cancer monitoring, is thrilled to announce the signing of a commercial partnership agreement with the Italian company, IT Health Fusion. The partnership will enable the commercialization of the DiviTum® TKa assay in Italy, offering an innovative and reliable solution for cancer monitoring.
Every year, approximately 17,000 Italian women are diagnosed with metastatic breast cancer. To help address this issue, BIOVIIIx’s subsidiary, IT Health Fusion, is taking the lead in introducing innovative treatments to the Italian market. Their initial focus will be on private insurance and out-of-pocket markets, which make up 40 percent of the market, in order to provide a much-needed solution to those affected.
We are thrilled to join forces with such a dynamic team that has a remarkable history of developing healthcare products for the market. Together, we are eager to tackle the expansive Italian market, which is one of the largest in Europe and offers exceptional opportunities with its influential key opinion leaders. Helle Fisker, VP of Commercialization for Biovica, expressed her enthusiasm for the partnership, stating “This is an exciting chance to make a real impact in the Italian market.”
Bringing the DiviTum TKa assay to the Italian market is an exciting opportunity for BIOVIIIx and IT Health Fusion. With a wealth of experience in the oncological pharmaceuticals field, the two organizations have the right contacts in hospitals and among healthcare professionals to ensure the successful implementation of the assay. According to CEO Davide Rosiello, “This is the perfect fit for our organization.”
The launch of IT Health Fusion’s DiviTum TKa is set to revolutionize the way metastatic breast cancer is diagnosed and monitored. With a team of eight experienced sales agents, all with connections in cancer diagnostic and monitoring departments, Fulvio Manzo, Sales and Marketing Manager of IT Health Fusion, is ready to get the ball rolling and make a difference in the lives of those suffering from this devastating disease. Let the launch activities begin!
About IT Health Fusion
IT Health Fusion is on a mission to save more lives and revolutionize healthcare. With the design, installation and validation of new generation cleanrooms designed for personalized oncology therapies and cell and tissue typing laboratories, plus a patented device/method for the automated preparation of therapies and systems for the governance of drug chain inside the hospital, IT Health Fusion is striving to reduce critical issues, improve people’s health and wellbeing, and keep health workers safe.
With extensive experience in the IVD market in Europe, including oncology, anatomic pathology, and infectious disease for both public and private hospitals, IT Health Fusion is paving the way for a healthier future.